Home Health Management of Parkinson’s Disease Deep Brain Stimulation: A Randomized Clinical Trial
Objective: Evaluate the efficacy of home health DBS postoperative management in an effort to reduce travel burden and improve access. Background: The travel required to…Should Amantadine DR/ER Be Considered Prior to Device-Aided Therapies for Parkinson’s Disease?
Objective: Evaluate delayed release/extended release amantadine (AMT DR/ER) capsules for motor complications in patients meeting 5-2-1 criteria for device-aided therapies (DAT) in advanced Parkinson disease.…CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)
Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Characterization of Acute Nausea During Dose Titration
Objective: Characterize acute episodes of nausea experienced by patients with Parkinson’s disease (PD) receiving apomorphine sublingual film (APL) for the on-demand treatment of “OFF” episodes.…Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial
Objective: To assess frequency and outcomes of impulsivity in study participants receiving bilateral subthalamic deep brain stimulation (STN-DBS) for treatment of Parkinson’s Disease (PD) who…CLE-600: Treating nocturnal and early morning OFF symptomology in Parkinson’s disease with the OLAR® platform
Objective: Development of a treatment for nocturnal and early morning OFF symptomology in Parkinson’s disease. Background: Levodopa Parkinson’s disease (PD) treatment is limited by its…The PD-1102 trial in advanced Parkinson’s disease: safety and clinical outcomes from a 3-year phase 1b study of AADC gene therapy administered via a posterior approach
Objective: To present 3-year safety and clinical outcome data from a phase 1b, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor…Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of entacapone: findings from the real-world OPTIPARK study
Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of entacapone…Influence of Dopamine Transporter Gene Polymorphism on Wearing Off
Objective: To study the influence of Dopamine transporter gene polymorphism on Wearing off (WO) through 19 items wearing off questionnaire (WOQ-19) Background: The dopamine transporter…Combined Plantar Stimulations Using a Novel Parkinson Shoe benefit Parkinson’s Disease Patients with Unresponsive Freezing of Gait
Objective: To explore the effect of combined vibratory and pressure stimulations in PD patients with unresponsive FOG and develop the innovative PD shoe. Background: Freezing…
- « Previous Page
- 1
- …
- 23
- 24
- 25
- 26
- 27
- …
- 132
- Next Page »